Back to results
US 12,345,712 B2Granted
Cancer antigen targets and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMichel Sadelain, Fabiana Perna
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.
Claims18
A method for producing an antigen-specific immunoresponsive cell, comprising introducing into an immunoresponsive cell:
- (a) a first nucleic acid encoding an antigen recognizing receptor that binds to EMR2, wherein binding of the antigen recognizing receptor to EMR2 is capable of activating the immunoresponsive cell, and
- (b) a second nucleic acid encoding a chimeric co-stimulating receptor (CCR) that binds to CLEC12A, wherein binding of the CCR to CLEC12A is capable of stimulating the immunoresponsive cell;
- wherein the antigen recognizing receptor binds to EMR2 with a binding affinity that is lower compared to the binding affinity with which the CCR binds to CLEC12A.
Dependencies are inferred from the claim text.